Incyte | INCY - Ebit


Incyte reported $-707.47M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agenus USD 15.05M 656K Mar/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
Exelixis USD 268.42M 20.01M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
MacroGenics USD -65.25M 33.36M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Moderna USD 130M 945M Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 411M Sep/2026
Novartis USD 1.78B 2.4B Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026